|1.||Apak, Hilmi: 2 articles (06/2014 - 10/2010)|
|2.||Ozdemir, Nihal: 2 articles (06/2014 - 10/2010)|
|3.||Wilhelm, Kathleen: 1 article (02/2015)|
|4.||Glaser, Anita: 1 article (02/2015)|
|5.||Liehr, Thomas: 1 article (02/2015)|
|6.||Carreira, Isabel M: 1 article (02/2015)|
|7.||Melo, Joana B: 1 article (02/2015)|
|8.||Gruhn, Bernd: 1 article (02/2015)|
|9.||Alhourani, Eyad: 1 article (02/2015)|
|10.||Rincic, Martina: 1 article (02/2015)|
|1.||Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
|2.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/1987 - "From January 1981 through July 1983, 141 children with newly diagnosed acute lymphoblastic leukemia were registered in a cooperative clinical study whose objective was to evaluate the toxicity and the feasibility of the German Berlin-Frankfort-Münster (BFM) protocol. "
01/01/1987 - "Treatment of acute lymphoblastic leukemia in children with the BFM protocol: a cooperative study and analysis of prognostic factors."
06/01/2014 - "A 17-year experience with ALL-BFM protocol in acute lymphoblastic leukemia: prognostic predictors and interruptions during protocol."
11/01/2008 - "Three hundred and seven children (1-14 years) with acute lymphoblastic leukemia (ALL) were treated with a modified BFM protocol 76/79 between 1985 and 2003. "
11/01/2008 - "Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol."
|3.||Burkitt Lymphoma (Burkitt's Lymphoma)
10/01/2010 - "This study aimed to assess the demographic data and treatment results of children who were diagnosed with Burkitt lymphoma and treated according to the Berlin-Frankfurt-Münster-95 (BFM) protocol in a single institution. "
04/01/2002 - "We have treated eight patients with Burkitt's lymphoma with a modified BFM protocol. "
04/01/2002 - "Burkitt's lymphoma: single-centre experience with modified BFM protocol."
08/01/2001 - "Recently published data suggest that the prothrombin G20210A variant, the TT677 methylenetetrahydrofolate reductase genotype, the factor V G1691A mutation, deficiencies of protein C, protein S, antithrombin, and elevated lipoprotein (a) concentrations were associated with venous thromboembolism in childhood patients treated according to the BFM protocol. "
|5.||Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
|1.||Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)
|2.||Excitatory Amino Acids
|5.||tau Proteins (tau Protein)
|6.||Prothrombin (Factor II)
|8.||factor V Leiden
|9.||formycin diphosphate (FDP)
|1.||Drug Therapy (Chemotherapy)